Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Very close. Nice to see spread narrowing.
TTTSF: TruTrace Technologies Announces Second Quarter 2020 Financial and Operating Results
5:30 PM ET 12/20/19 | Dow Jones
December 20, 2019 -- (TruTrace Technologies) --
(TheNewswire)TORONTO - TheNewswire - December 20, 2019 - TruTrace Technologies Inc. (CSE:TTT) (CNSX.TTT.CN)(OTC:TTTSF) ("TruTrace" or the "Company"), creator of the first fully-integrated blockchain platform that registers and tracks intellectual property for the cannabis industry, today announced its financial and operating results for the three and six months ended October 31, 2019. All figures are stated in Canadian dollars.
"In the second quarter, we continued to execute on our most important priorities, highlighted by the ongoing implementation of the Shoppers Drug Mart Pilot Program and strategic alliance with Deloitte Canada, as well as the implementation of our platform with several licensed producers in the tracking of their intellectual property in their distribution of medical cannabis," said TruTrace Technologies CEO Robert Galarza. "We are very excited to become the first traceability platform in this sector to achieve these milestones with such strong partners."
Second Quarter 2020 Financial Highlights
- The Company generated revenue of $303,520 in the second quarter of fiscal 2020, compared to nil in Q2 2019 and $48,000 in Q1 2020. Revenue growth was primarily driven by implementation fees associated with the use of TruTrace technology.
- Net loss and comprehensive loss was $914,652 in the second quarter of 2020, compared to approximately $2.3 million in Q2 2019. The Company reported significantly reduced corporate development, general & administrative, salaries & benefits, and stock-based compensation expense due to efficiency initiatives and the impact of listing expenses related to the Company's reverse take-over in the prior-year period.
- Loss per share was $0.01 in Q2 2020, compared to a loss of $0.03 in Q2 2019.
- Funds used in operations totaled $707,665 in the quarter, compared to approximately $1.6 million in Q2 2019.
- Cash on hand was approximately $121,000 as at October 31, 2019, compared to approximately $1.2 million at April 30, 2019.
Operating Highlights
- Completed Phases 1 and 2 of the Shoppers Drug Mart ("Shoppers") medical cannabis verification pilot program (the "Pilot Program"), which is intended to increase transparency, interoperability, and product identification within the medical cannabis industry. The Pilot Program uses TruTrace's StrainSecure(TM) technology as a central hub for identity management, asset tracking, validation, and product authentication. StrainSecure will also serve as a master registry for standardized testing, product verification and quality assurance.
- Licensed producers (LPs) participating in the Pilot Program include: Aphria Inc., Aurora Cannabis Inc., The Flowr Corporation, Tilray Canada Ltd., United Greeneries (a subsidiary of Harvest One Cannabis Inc.), WeedMD Inc. and Zenabis Global, Inc.
- The Company added several partners to the StrainSecure ecosystem to contribute to the successful implementation of the platform, including cannabis testing lab Anandia, agricultural technology company Segra International Corp., testing and analytical services company Sigma Analytical, and clinical research and telemedicine platform AdvancedCare.
- Deloitte and TruTrace announced a strategic alliance to deliver blockchain product-traceability solutions to the cannabis industry. The Company expects the strategic alliance to lead to additional business development opportunities.
- During the second quarter, the Company completed several non-brokered private placement financings of common shares and convertibles debentures, raising total net proceeds of approximately $967,000.
Subsequent Events
- TruTrace and other Pilot Program participants continue to work towards full production and implementation of the Company's StrainSecure platform, and advancing the Pilot Program beyond its initial scope.
- In November 2019, TruTrace announced that Colombia-based multinational cannabis producer Clever Leaves has joined the StrainSecure platform in order to bring standardization and product validation into its international distribution strategy.
Outlook
"The Shoppers Pilot Program has provided a unique opportunity to validate the effectiveness of our StrainSecure platform, with the support of cornerstone clients and partners," said Robert Galarza. "Demonstrating the functionality and benefits of a new technology under real-world conditions is a vital step on the way to more widespread adoption. We expect to continue to execute on key deliverables in the coming months as the Pilot Program progresses towards full implementation."
With the launch of its StrainSecure(TM) platform, TruTrace offers an easily-integrated blockchain solution that tracks cannabis from Genome to Sale(TM) through the supply chain and provides actionable quality assurance and real-time testing data to the cannabis industry.
The Company's goal is to build a framework for licensed producers as well as micro cultivators that are entering the newly legalized ecosystem, helping them to easily and inexpensively move their products through testing procedures. TruTrace then places that testing data on the blockchain for immutability and intellectual property protection, and feed that information through the ecosystem for full visibility into the supply chain. The resulting outcome is a trustworthy source of product and inventory data that can be used to support anything from clinical trials to medical efficacy studies, as well as providing regulators, medical practitioners, patients, and even retail consumers a much-desired level of actionable intelligence. With TruTrace, all parties can see whether a product is clean, safe, pesticide-free, and truly is what it claims to be.
More detailed financial information and analysis with respect to TruTrace's results of operations are available in its unaudited financial statements and management's discussion and analysis for the period ended October 31, 2019, both of which can be found on SEDAR atwww.sedar.com.
About TruTrace Technologies:
TruTrace Technologies has developed the first integrated blockchain platform to register and track intellectual property in the cannabis industry. TruTrace's technology allows cannabis growers and breeders to identify and secure rights to their intellectual property. It also streamlines the administrative process and reduces the costs of genetic and mandatory quality-control testing for legal cannabis. TruTrace's technology is proprietary, immutable and cryptographically secure, thereby establishing an accurate and permanent account for cannabis strains from ownership to market.
For More Information:
Robert Galarza, Chief Executive Officer and Director, 844-656-3629. Investor Inquiries: Swapan Kakumanu, Chief Financial Officer, 844-656-3629, swapan@trutrace.co
Disclaimer for Forward-Looking Information
This news release includes forward-looking information within the meaning of Canadian securities legislation, concerning the business of TruTrace, including statements regarding: the intention that the Pilot Program willincrease transparency, interoperability, and product identification within the medical cannabis industry; that the addition of several partners to the StrainSecure ecosystem is expected to contribute to the successful implementation of its platform;that full production and implementation of TruTrace's StrainSecure platform are proceeding; the expectation that the strategic alliance with Deloitte to lead to additional business development opportunities; and the expectation that demonstrating the functionality and benefits of StrainSecure under real-world conditions will lead to more widespread adoption.
Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that it will prove to be correct and actual results and future events could differ materially from those anticipated in such information. Forward-looking information necessarily involves known and unknown risks, including, without limitation, risks associated with: general economic conditions; adverse industry events; loss of markets; future legislative and regulatory developments in Canada, the United States, and elsewhere; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; and other risks beyond the Company's control. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties and other factors, many of which are beyond the control of the Company. Readers are cautioned not to place undue reliance on any forward-looking information contained in this news release. Forward-looking information contained in this news release is provided as of the date of this news release. The Company disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
Copyright (c) 2019 TheNewswire - All rights reserved.
> Dow Jones Newswires
December 20, 2019 17:30 ET (22:30 GMT)
PLEASE READ THE IMPORTANT DISCLOSURES BELOW.
That would be a welcome sight!
Nice find, xanadu.
CEO: Why telehealth can 'upend' health care like Amazon did retail
https://finance.yahoo.com/news/telehealth-to-upend-health-care-like-amazon-did-retail-american-well-chief-says-153005469.html
Anjalee Khemlani
Senior Reporter
Yahoo Finance December 18, 2019: The fusion of video technology and medical diagnoses still carries the promise of disrupting health care at lower cost, according to American Well co-CEO and president Roy Schoenberg — even though it will require the health care industry to pivot significantly.
Telehealth is used in a variety of formats, including web chats, phone calls and video conferencing, and is employed by health care operators like insurance companies, doctor’s offices, a hospital or pharmacy.
Its original purpose in the health care system was as an urgent care solution — a way to save health insurers and patients the cost of an emergency visit in exchange for a convenient and quick analysis from a video chat.
But 15 years later, there is a realization that telehealth is lagging in its original promise, in part due to slow sales cycles and low adoption of the technology. Yet Schoenberg insisted to Yahoo Finance that the field can still fulfill its original mission.
“The way we look at telehealth today is the way people looked at Amazon when Amazon was selling books online,” he said.
“Amazon completely upended the retail business, they were trying it out through books. Telehealth is going to upend health care and it’s tried it out through urgent care,” Schoenberg added.
Yet the debate over how telehealth can make its leap into Amazon’s league is still an open question, especially amid cost concerns.
American Well currently boasts 150 million users, including 55 health insurers, as partners, as well as a handful of employers and other retail partners. They also work with 2,000 hospitals, where a significant portion of business comes from. Unlike competitors such as Teladoc (TDOC), American Well is largely paid through insurers instead of employers or independently.
Via a partnership with Cisco, the privately-owned American Well is looking to bolster those numbers by expanding telehealth to elder patients. American Well previously announced plans to harness in-home TV sets to deliver broad-based medical advice, planning to ride the transformational wave of an industry that’s modernizing — slowly but surely.
That plan is, despite some hurdles, still set to launch in 2020, Schoenberg said.
“I think the relationship is changing fast. Unlike health care that usually moves in a glacial pace, this is technology and technology goes much faster,” Schoenberg said.
“This is the most exciting time that I can probably remember in telehealth, because for the last maybe 13 to 14 years, what we were going to do was limited to urgent care,” he said, noting that the evolution of technology in the health care field has opened up brand new frontiers.
“Now that the ability to deliver health care over technology has become an acceptable way of practicing medicine and delivering care, now, everybody has started rewriting the whole world of health care,” Schoenberg stated.
As more advanced tech takes root in the field, hospitals and health systems “are reimagining where they are going to care for patients,” the executive said.
Like a concierge
Schoenberg launched American Well back in 2006 with his older brother, Ido. At the time, the two entered a space where a remote visit was seen as transactional — no commitments, no history, no promise of future interactions.
Now, the company sees itself as “in the business of logistics. What we do, what we run, is a switchboard. It’s a distribution for live health care services,” the CEO added.
With more people willing to use it — and convinced that it is a safe enough method for health care despite occasional complaints— Schoenberg believes American Well has found the recipe for success.
Telehealth lets doctors find specialists if their hospital or health system doesn’t have one, while oncologists can follow-up with cancer patients from the convenience of their home. Meanwhile, physicians can follow-up with their patients any time.
Enhanced connectivity through mobile apps and electronic health records makes it seem “as if you signed up to a very good concierge practice,” Schoenberg said.
Calling the new uses of the technology “a new insurance product,” he described the advancements as “a new way to imagine...your journey in consumption of health care. It’s way broader than the urgent care we have today.”
With billions in capital flowing to digital health overall, Schoenberg told Yahoo Finance that there are benefits to American Well staying private, but in terms of future growth, all options are on the table.
The company has already raised half a billion dollars, and expects telehealth will remain a hot ticket item for venture capital funding for future growth.
Staying private “gives you a lot of autonomy to make decisions that are more disruptive in the market, you can be more strategic that companies who have to move quarter by quarter to generate numbers,” he said.
In addition, the technology is developing and being reimagined at a pace that requires quick and nimble adaption— which would be harder as a public company, Schoenberg said.
“One of the places you want to be when that happens is have ample flexibility ...to bring in a lot of other capabilities that you can’t buy with pure cash,” he said. “You have to buy with currency that goes beyond that currency that has long staying power.”
Anjalee Khemlani is a reporter at Yahoo Finance. Follow her on Twitter: @AnjKhem
Read the latest financial and business news from Yahoo Financ
Nextleaf Solutions Enters into Patent Licensing Agreement
Royalty anticipated to deliver over $3.0MM to the Company in 2020(i)
VANCOUVER, Dec. 17, 2019 /CNW/ - Nextleaf Solutions Ltd. ("Nextleaf", "OILS", or the "Company") (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA), a Coquitlam-based company developing intellectual property for the extraction and purification of cannabinoids, is pleased to announce that it has entered into a strategic agreement (the "Agreement") with a British Columbia-based cannabis processing equipment distribution company (the "Licensee").
The Agreement permits the Licensee, on a non-exclusive basis, to commercialize and distribute certain intellectual property, specifically, three issued and pending patents related to post-extraction processing equipment ("IP") developed by Nextleaf. OILS will provide the Licensee with initial working capital and strategic support during the indefinite term of the Agreement. OILS may terminate the Agreement if the Licensee does not meet certain minimum annual sales targets.
OILS will receive a royalty equal to 20% of the Licensee's gross revenue from all sources (the "Royalty") in exchange for, among other consideration, the licensed IP. Based on the Licensee's current product backlog and 2020 projections, OILS estimates the Royalty could yield over $3,000,000 in royalty fees to Nextleaf in the 2020 calendar year, with initial revenue expected to commence in the immediate term.(i)
"We believe this is an ideal partnership with a company whose management has a proven track record of building one of the industry's largest cannabis processing equipment distributors," stated Charles Ackerman, Chief Financial Officer of Nextleaf. "This deal allows OILS to continue its work to efficiently monetize its patent portfolio globally. It also brings closer to its previously announced goal of $5,000,000-$10,000,000 in gross revenue from IP licensing alone in the next 12 months.(ii) We believe IP licensing has the potential to represent up to 10-20% of our gross annual revenue" continued Ackerman.(i)
In addition to the development and monetization of its IP portfolio, OILS continues to focus on assisting Nextleaf Labs Ltd., a Health Canada licensed standard processor, to reach full commercial production including the production and sale of bulk CBD and THC oils. Nextleaf expects to be in a position to announce additional commercial agreements during the first calendar quarter of 2020.
About Nextleaf Solutions
Nextleaf Solutions Ltd. ("OILS") is developing disruptive intellectual property for the extraction and distillation of cannabinoids. OILS owns a portfolio of 10 issued patents pertaining to industrial-scale production of distilled CBD and THC oils, the key ingredients used in the manufacturing of standardized cannabinoid based products. OILS commercializes its IP portfolio through IP licensing, B2B processing, and supplying THC and CBD oils to qualified Canadian and international partners through Nextleaf Labs Ltd., a Health Canada licensed standard processor.
Nextleaf Solutions trades as OILS on the Canadian Securities Exchange, OILFF on the OTCQB Market in the United States, and L0MA on the Frankfurt Stock Exchange.
Follow OILS across social media platforms: Twitter, LinkedIn, Facebook, and Instagram.
www.nextleafsolutions.com
On behalf of the Board of Directors of the Company,
Paul Pedersen, CEO
CAUTIONARY STATEMENT
Certain statements contained in this press release constitute "forward-looking statements". All statements other than statements of historical fact contained in this press release, including, without limitation, those regarding the Licensee's current backlog and projections for the 2020 calendar year, the Royalty expected to be received by the Company during the 2020 calendar year, the Company's ability to capitalize on its IP portfolio and in jurisdictions outside of Canada, the Company's expected gross revenue from IP licensing during the 2020 calendar year, the percentage of the Company's revenue expected to be received from IP licensing, the Company's expectations regarding the entering into of new commercial agreements in the first quarter of 2020, and the Company's strategy, plans, objectives, goals and targets, and any statements preceded by, followed by or that include the words "believe", "expect", "aim", "intend", "plan", "continue", "will", "may", "would", "anticipate", "estimate", "forecast", "predict", "project", "seek", "should" or similar expressions or the negative thereof, are forward-looking statements. These statements are not historical facts but instead represent only the Company's expectations, estimates and projections regarding future events. These statements are not guarantees of future performance and involve assumptions, risks and uncertainties that are difficult to predict. Therefore, actual results may differ materially from what is expressed, implied or forecasted in such forward-looking statements. Additional factors that could cause actual results, performance or achievements to differ materially include, but are not limited to the risk factors discussed in the Company's MD&A for the most recent fiscal period. Management provides forward-looking statements because it believes they provide useful information to investors when considering their investment objectives and cautions investors not to place undue reliance on forward-looking information. Consequently, all of the forward-looking statements made in this press release are qualified by these cautionary statements and other cautionary statements or factors contained herein, and there can be no assurance that the actual results or developments will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, the Company. These forward-looking statements are made as of the date of this press release and the Company assumes no obligation to update or revise them to reflect subsequent information, events or circumstances or otherwise, except as required by law. The CSE has not reviewed, approved or disapproved the contents of this press release.
______________________________
INPX blowing up again AH.
That's what I was thinking, too.
Looked all over, but found nothing. Jumped out before close as "no reason" was just too speculative to hold.
Bought .049 when I saw volume. Anyone know why?
LOL, wrong board. Sorry.
Sweet move this afternoon. Don't know why.
Nice find, saladtpb. Should hear news from NetObjex collaboration soon,
GTX Corp Signs Collaboration Agreement with NetObjex
New partnership will provide the integration of the GTX Track & Trace products with the NetObjex Artificial Intelligence, Blockchain and IoT platform.
LOS ANGELES CALIFORNIA , Oct. 02, 2019 (GLOBE NEWSWIRE) -- GTX Corp (OTCQB: GTXO), a pioneer and global technology provider in the field of wearable GPS human and asset tracking systems and Real-Time Location Systems (RTLS) wandering assistive technology, today announced signing a collaboration agreement with Netobjex, Inc., an Irvine CA. based Intelligent and Integrated Automation platform for tracking, tracing and monitoring digital assets across different industry verticals by leveraging the power of IoT, AI, and Blockchain technologies.
Under the agreement, certain GPS, BLE and NFC based GTX devices will be integrated into the NetObjex backend platform and made available to the NetObjex vertical channel partners
GTSM on Bid, too. OTCX was on the Bid for about 20 minutes today, shortly after open.
Kingdom says another SeekingAlpha SOLI article is in progress.
LOL, did you forget about 2020, MWM?
Will post it if I get any response.
Just messaged The Seeking Alpha SOLI author, Kingdom Capital, to see if he's keeping track of the progress SOLI has made since coming off the Greys.
Yup, I added on Monday's news.
LOL, a totally skeptical friend just bought some based on this week's news.
Me, too. You guys were like the 3 Musketeers.
And other times you reverted to the 3 Stooges. Always amusing.
Anyone else notice the Audit was received by SOLI in early November?
CareClix, Inc. a wholly owned subsidiary of Solei Systems, Inc. (OTC PINK:SOLI) is pleased to announce, effective November 4th, 2019 it has received the American Institute of Certified Public Accountants (AICPA) Service Organization Control 2 (SOC 2) report.
Kinda makes you wonder what other news they might be sitting on.
Remember, Monday's PR about the MAXIS partnership came a few hours after the MAXIS PR. I'm thinking they might not have known the MAXIS PR was coming and were caught a little flat-footed. Only after a couple of IHUB'ers contacted SOLI to ask why no PR was released did the SOLI PR suddenly appear. And, basically, SOLI repeated the MAXIS PR.
ALEXANDRIA, VA / ACCESSWIRE / December 3, 2019 / Solei Systems Inc (OTC PINK:SOLI) is pleased to announce its partnership with with MAXIS GBN. Following is the press release generated by MAXIS GBN: MAXIS Global Benefits Network (MAXIS GBN) has selected CareClix, a leading telemedicine solutions company, as its global provider of telemedicine services.
Again, kinda makes me wonder what other developments they might have in pocket.
Thanks, MWM, you and Ed were always two of my favorites back in the day.
More SOC 2 Audit info
SOC Audit and Report
The cost for a typical SOC Type 1 starts at $20,000, and SOC Type 2 starts at $30,000. Managing the cost of a SOC Report is of course very important – and a sound approach, with experienced assessors will provide long-term value to the organization.
The SOC 2 reporting process can take anywhere from 4 weeks – 18 months on the extreme ends of the spectrum (6 weeks – 3 months on average).
Here are six steps you can take to prepare.
Define the operating goals of your audit. ...
Define the scope of your SOC 2 audits. ...
Address regulatory and compliance requirements. ...
Review and write security procedures. ...
Perform a readiness assessment. ...
Evaluate and hire a certified auditor.
https://phoenixnap.com/blog/soc-2-audit-compliance
Even auditor, Schellman & Company, LLC, pretty impressive.
"The audit conducted by Schellman & Company, LLC found that CareClix meets the SOC 2 standards for security and availability trust services principles with zero exceptions listed."
https://www.prnewswire.com/news-releases/florida-based-firm-schellman-recognized-as-a-top-100-cpa-firm-300617563.html
Florida-Based Firm, Schellman, Recognized as a Top 100 CPA Firm
(PRNewsfoto/Schellman & Company, LLC)
Mar 21, 2018, 11:00 ET
TAMPA, Fla., March 21, 2018 /PRNewswire/ -- Achieving a goal many years in the making, Tampa based CPA firm, Schellman & Company, LLC (Schellman), a leading provider of attestation and compliance services, has been named one of the largest CPA firms in the United States by Accounting Today. Previously unranked, Schellman's annual revenue of nearly $50 million earned the company the 89th spot in the latest "Top 100 Firms" report, along with the distinction of being the youngest company among the ranked firms.
Schellman is unique even among the Top 100 firms, as it is the only firm that does not provide traditional accounting services, such as financial statement audits or tax preparation. Schellman's practice instead specializes in System and Organization Controls (SOC) examinations, as well as ISO, PCI, HITRUST, and FedRAMP compliance services.
With demand rapidly growing for those services, Schellman's annual revenue growth propelled it into the Top 100 list. In fact, Schellman had the largest move up the 2018 rankings of any Top 100 firm, excluding mergers and acquisitions. "It has been our goal to be in the Top 100 for the last few years," says Schellman. "Now we have plans to become a Top 50 firm within the next 10 years due to the exponential growth in demand for our services."
Making history is nothing new at Schellman. Founded in 2002, Schellman was the first CPA firm to provide SOC examinations, formerly known as SAS 70 audits, as its sole service. Later, Schellman became the first CPA firm accredited to perform ISO certifications, and remains the only CPA firm dually accredited by the United States (ANAB) and United Kingdom (UKAS) accreditation bodies. The company was also the first CPA firm accredited as a FedRAMP 3PAO, and performs more 3PAO assessments than any CPA firm in the world. Schellman's impact on the industry has not gone unnoticed. In 2015, Schellman earned the distinction of being the only CPA firm ever selected as a "Cool Vendor" by the global research firm Gartner.
Avani Desai, executive vice president, attributes Schellman's accomplishments to an unwavering commitment to quality. "Schellman has built a reputation for its professionals being passionate about compliance. Between that, constant innovation and fundamental respect for the art of professional services, quality and success have followed." —success that now includes a Top 100 ranking.
"It is truly a historic achievement for our team," said company President, Chris Schellman. "We created a niche in the accounting industry and permanently changed the competitive landscape for specialized firms."
Accounting Today is a leading information resource for public accounting industry. The 2018 "Top 100 Firms" ranking can be found on their website at AccountingToday.com.
About Schellman & Company
Schellman & Company, LLC is a leading provider of attestation and compliance services—the only company in the world operating under one legal entity that is a CPA firm, a globally approved PCI QSA, an ISO Certification Registrar, HITRUST CSF Assessor, and a FedRAMP 3PAO.
Schellman & Company, LLC
Avani Desai
pr@schellman.com
SOURCE Schellman & Company, LLC
Related Links
http://www.schellman.com
Can't overstate importance of HIPAA and HITECH compliance!
"The certification further reinforces CareClix's leading position on compliance and security within the telemedicine industry. CareClix is HIPAA and HITECH compliant, providing the upmost care in health information privacy."
Worth reading: https://www.virtru.com/blog/hitech-compliance-checklist-are-you-doing-enough-to-protect-yourself/
Another AXA Telemedicine link/article
https://www.axa.com/en/spotlight/story/telemedicine-universal-access-to-healthcare
Telemedicine: universal access to healthcare
As the first private company to launch remote medical consultations for French patients, AXA is enhancing its offering in pace with regulatory and technological progress. In France, these new services have already proved successful, with high user satisfaction ratings. A good example is the AXA Partners platform, a telemedicine service accessible to 5 million beneficiaries 24/7 by phone or online through www.bonjourdocteur.com
Caring for Life
Apr 24, 2019
Working from a 100 m2 call center in the suburbs of Paris, doctors and nurses take daily calls from patients, AXA clients and affiliated top-up insurance companies. Nawal, a hospital nurse, is their first point of contact. “Before transferring patients to a doctor, I welcome them and identify their needs. Unlike medical secretaries, my training as a nurse enables me to quickly detect and prioritize serious or urgent cases or even guide them to an emergency service right away.”
These first elements are communicated to the doctor who receives the transferred call. “It’s a first line of questioning. In a teleconsultation, it’s important for us not to miss anything. For example, one of my patients didn’t think to tell me she was seven months’ pregnant, since she was so used to people noticing it!” commented Dalila, a general practitioner.
“Remote consultations require experience”
Like her colleagues, Dalila works for 10 hours a week on the platform. This rota enables the service to integrate a wide variety of profiles. As a forensic medical practitioner, she has also worked in hospital emergency departments and in a town-center office. “Remote consultations take experience. I don’t know if I could have done this after I’d just come out of medical school.” Philippe confirmed, “We learn to develop new senses, to understand what people are not saying. To interpret the signs, you need to have some years of practice under your belt.”
Philippe has worked in counseling and now works as a liberal practitioner. He sees telemedicine as a much-needed service for people who have trouble getting an appointment due to the shortage of doctors. The platform serves diverse types of patients, but what they all have in common is “being comfortable with the fact of not facing physically a doctor and having difficulty getting an appointment to suit their agenda. Usually, these people would give up trying to see a doctor and might miss serious symptoms.” A few months ago, Dalila diagnosed meningitis in a 10-year-old girl, who had been treated with aspirin.
A service to complement local surgeries
After a teleconsultation, several solutions are possible. First, explaining what to do if symptoms get worse, can sometimes be enough to reassure patients. They may also be redirected to a specialist partner through another teleconsultation platform, or emergency services. The doctors can also write prescriptions when necessary, but not medical certificates or sick notes without a physical examination.
Related content
Discover AXA's 2018 Integrated Report
read more
While remote examination techniques continue to make great strides, “teleconsultations will not replace regular follow-up with a regular doctor, but they are a great way to provide a first response to patients who are pushed for time or cannot easily access treatment,” concluded Philippe. They also offer a credible solution to the health issues encountered by many emerging countries: developing universal access to healthcare, while relieving emergency services and reducing the cost of healthcare systems.
A cure for medical deserts
In 2019, a type of medical inequality cuts across many regions: “medical deserts”, areas without sufficient numbers of doctors – particularly physicians – to provide everyone with the same access to quality healthcare. This is not due to a lack of health professionals at the national level, but instead to their unequal distribution across territories.
Many countries are affected. In France, 8% of the population lives in one of the 9,000 municipalities that lack physicians. This situation is all the more concerning as it relates to all region types - rural and urban - and because it is likely to deteriorate, as not all retiring physicians are being replaced. The same observation can be made elsewhere in Europe, with expanding medical deserts occurring in the United Kingdom, Belgium and Germany for example, and many other instances throughout the world. For example, the National Rural Health Association in the United States reports that 77% of rural areas suffer shortages of primary healthcare professionals, while 9% do not have a doctor.
Given the situation, what actions can be implemented? Public authorities are tackling the issue through various trials: incentives to encourage young doctors to move to disadvantaged areas, the creation of interdisciplinary health centers, better cooperation between health professionals, establishment of mobile medical services – such as health buses that travel to remote areas... And, of course, telemedicine to respond to emergency situations with remote diagnoses, and for everyday healthcare issues.
To make progress in this field, AXA and the Hauts-de-France region have joined forces to launch a medical teleconsultation program. Established in Marconne, in the Pas-de-Calais French department, this system enables each patient to benefit from on-site nurse support while their condition is monitored remotely by a doctor, thus combining human interaction with the use of new technologies.
GTXO: This GPS Firm Knows Where it’s at.
https://www.baystreet.ca/stockstowatch/6789/This-GPS-Firm-Knows-Where-
Technology geared to getting people around, covering the shortest ground from Point A to B, is getting more sophisticated all the time.
Los Angeles-headquartered GTX Corp. (OTC:GTXO) made waves Monday with an eye-popping set of financial numbers for its third quarter.
GTX is a pioneer in the field of wearable GPS, people and asset tracking Location-Based Services and Real-Time Location Systems, announced revenues of about $340,000 compared to approximately $195,000 for the comparable period in the prior-year for an increase of approximately $145,000, or 74%.
Gross profit margin for the three months ended September 30, 2019 was 89% compared to 77% for the three months ended September 30, 2018. This increase in margin is primarily due to the increase in higher margin IP licensing, Professional Services and subscription revenue during these periods.
Income from operations for the quarter came in at $73, 000, as compared to a loss of $227,000 for the comparable period in the prior year.
GTX is a U.S. military contractor and has multiple wearable tracking products sold through its online store, Amazon and authorized re-sellers and distributors servicing customers across the globe.
Shares in GTXO skyrocketed 67.9% to 94-100ths of a cent, on volume of 210,000
TruTrace Technologies signs Clever Leaves to Cannabis Validation Testing Program
7:00 AM ET 11/19/19 | Dow Jones
November 19, 2019 -- (TruTrace Technologies) --
(TheNewswire)Toronto - TheNewswire -November 19, 2019 - TruTrace Technologies Inc. (CNSX:TTT.CN) (OTC:TTTSF) ("TruTrace" or the "Company"), creator of the first fully-integrated blockchain platform that registers and tracks intellectual property for the cannabis industry, and Clever Leaves, a leading vertically-integrated global company and fully licensed producer of pharmaceutical-grade medical cannabis and hemp extracts, announced today that Clever Leaves has joined TruTrace's StrainSecure(TM) platform to bring standardization and product validation into its international distribution strategy.
The StrainSecure platform allows partner laboratories to collect plant testing data and perform genomic verification in plant batches which are then registered in a blockchain-enabled database for intellectual property protection and strain validation. All information gathered from the plants, including their molecular and chemical makeup, can be tracked via the program.
The StrainSecure(TM) platform will collect, register, manage, track and publish verified testing data of Clever Leaves' cannabis plant DNA and strains, including prospective shipments into the Canadian market. The platform will enable Clever Leaves to validate its medical cannabis strains and provide its customers with increased transparency about the authenticity, quality and origin of its products.
"Our Genome-to-Sale(TM) software continues to gain traction as industry stakeholders increasingly recognize the critical importance of being able to provide account for the origin and quality of cannabis products," said TruTrace Technologies CEO Robert Galarza. "Clever Leaves is on track to become a major international supplier, and we are pleased to provide our full support of their initiatives at this early stage of their expected growth."
"We are committed to establishing full transparency and traceability of our strains. This is especially important for medical cannabis, where clinical outcomes and research conclusions are dependent on a level of consistency that can only come from being able to track a product's origin; the TruTrace platform is uniquely capable of providing this assurance," said Andres Fajardo, President of Clever Leaves. "We look forward to working with TruTrace and Shoppers Drug Mart on this initiative as we pursue our goal of becoming the largest medical cannabis company in the world." In February 2019, Clever Leaves became the first company authorized by Health Canada to import cannabis from Colombia into Canada.
About TruTrace Technologies:
TruTrace Technologies has developed the first integrated blockchain platform to register and track intellectual property in the cannabis industry. TruTrace's technology allows cannabis growers and breeders to identify and secure rights to their intellectual property. It also streamlines the administrative process and reduces the costs of genetic and mandatory quality-control testing for legal cannabis. TruTrace's technology is proprietary, immutable and cryptographically secure, thereby establishing an accurate and permanent account for cannabis strains from ownership to market.
About Clever Leaves:
Clever Leaves is a multi-national cannabis company operating in compliance with federal and state laws, with an emphasis on ecologically sustainable, large-scale cultivation and processing as the cornerstone of building out distribution and brands. Clever Leaves is a leading vertically integrated producer of medical cannabis and hemp extracts and is currently cultivating over 1.5 million square feet of greenhouses under Good Agricultural and Collection Practices (GACP) in Colombia, with expected expansion to 2.3 million square feet by the end of 2019 and the goal of reaching 10 million square feet by 2021. Clever Leaves obtained its Good Manufacturing Practices (GMP) certification from INVIMA, Colombia's food and drug regulatory agency, after inspection of its top-of-the-line extraction facility and is in the process of being certified with European Good Manufacturing Practices (EU GMP). Clever Leaves' first extraction facility is capable of extracting 24,000 kilograms of dried flower currently, with expansion underway to increase expected extraction capacity to 324,000 kilograms of dried flower per year by mid-2020. Clever Leaves is also expanding its cultivation and extraction capabilities to Portugal, where it currently owns over 9 million square feet of property with over 100,000 square feet of greenhouses and anticipates its first harvests in 2020. With offices in Canada, Colombia, Germany, Portugal, the United Kingdom and the United States, Clever Leaves is one of the world's largest hemp and medical cannabis producers.
For More Information:
Swapan Kakumanu
Chief Financial Officer, TruTrace Technologies
844-656-3629
swapan@trutrace.co
Diana Siguenza
Strategic Communications Director
+57 310-236-8830
diana.siguenza@cleverleaves.com
www.cleverleaves.com
Press contacts:
McKenna Miller
KCSA Strategic Communications
347.487.6197
Cleverleaves@kcsa.com
Disclaimer for Forward-Looking Information
This news release includes forward-looking information within the meaning of Canadian securities legislation, concerning the business of TruTrace, including statements regarding: the ability of theStrainSecure platform to bring standardization and product validation into Clever Leaves' international distribution strategy; that the StrainSecure tm platform will collect, register, manage, track and publish verified testing data of Clever Leaves' cannabis plant DNA and strains, including prospective shipments into the Canadian market;the ability of the StrainSecure platformto enable Clever Leaves to validate its medical cannabis strains and provide its customers with increased transparency about the authenticity, quality and origin of its products; that TruTrace's Genome-to-Sale(TM) software continues to gain traction as industry stakeholders increasingly recognize the critical importance of being able to provide account for the origin and quality of cannabis products; Clever Leaves' success in becoming a major international supplier and its expected growth; Clever Leaves' goal of becoming the largest medical cannabis company in the world; Clever Leaves' expected expansion to 2.3 million square feet by the end of 2019 and the goal of reaching 10 million square feet by 2021;Clever Leaves' planned expansion to increase its extraction capacity to 324,000 kilograms of dried flower annually by early next year; and Clever Leaves' anticipated first harvests in 2020. Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that it will prove to be correct and actual results and future events could differ materially from those anticipated in such information. Forward-looking information necessarily involves known and unknown risks, including, without limitation, risks associated with: general economic conditions; adverse industry events; loss of markets; future legislative and regulatory developments in Canada, the United States, and elsewhere; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; and other risks beyond the Company's control. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties and other factors, many of which are beyond the control of the Company. Readers are cautioned not to place undue reliance on any forward-looking information contained in this news release. Forward-looking information contained in this news release is provided as of the date of this news release. The Company disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
Copyright (c) 2019 TheNewswire - All rights reserved.
> Dow Jones Newswires
November 19, 2019 07:00 ET (12:00 GMT)
Last paragraph: "Harvest One Cannabis' fiscal 4Q delivers strong revenue boosted by consumer and medical segments"
https://www.proactiveinvestors.com/companies/news/905829/harvest-one-cannabis--fiscal-4q-delivers-strong-revenue-boosted-by-consumer-and-medical-segments-905829.html
For the three and 12 months ended June 30, 2019, the Vancouver company posted net revenues of $3 million and $11.5 million respectively
Harvest One Cannabis Inc - Harvest One Cannabis' fiscal 4Q delivers strong revenue boosted by consumer and medical segments
The Vancouver-based company’s subsidiary inked a supply agreement with Canada's largest retail pharmacy chain, Shoppers Drug Mart, to supply Satipharm branded medical cannabis products
Harvest One Cannabis Inc (CVE:HVT) (OTCMKTS:HRVOF) revealed Tuesday that its fiscal fourth-quarter saw strong revenue growth within its consumer and medical segments.
In a statement accompanying the global cannabis company’s latest numbers, Harvest One CEO Grant Froese said: "We are delighted with the company's progress throughout the fourth quarter and fiscal 2019 as we build a platform for long-term growth across all our segments.”
"In the fourth quarter, we showed strong revenue growth within our consumer and medical segments while our cultivation segment remained steady prior to adding the necessary scale through the expansions of our facilities,” he added.
READ: Harvest One Cannabis wins cultivation license for Mission Road facility on Vancouver Island
For the three and 12 months ended June 30, 2019, the company achieved net revenues of $3 million and $11.5 million, respectively, representing a 489% and 1,479% increase from the same periods in 2018.
Its products are sold in some 38,000 retail distribution points around the globe, including, Walmart US, CVS, Kroger, Shoppers Drug Mart, Loblaw, Holland & Barrett, and Boots.
“We have developed excellent and trusted relationships with our provincial partners ensuring a valuable route to market,” said Froese.
Inked key deals
“We have also made the necessary investments to ensure we are one of the first to market with derivative cannabis products following the recent legislation changes in Canada," he added.
The firm recently inked a deal to acquire 100% of the issued and outstanding common shares of Delivra Corp. Additionally, the Vancouver-based company’s subsidiary United Greeneries entered into a supply agreement with Canada's largest retail pharmacy chain, Shoppers Drug Mart, to supply Satipharm branded medical cannabis products.
"Our first quarter fiscal 2020 revenues look promising for growth across all our divisions, with the addition of new Satipharm wholesale agreements and the addition of Delivra revenue to our consumer segment,” pointed out Froese.
The company said that during the fiscal fourth quarter, it cemented an agreement to distribute Satipharm's proprietary 10 mg CBD GelPell capsules through Holland & Barrett, Europe's largest retailer of nutritional supplements and wellness products.
Harvest One serves as an umbrella over three wholly-owned subsidiaries: United Greeneries, which is a licensed cannabis producer; Satipharm, which develops cannabis-based health products; and Dream Water, which offers consumer sleep aids.
In its statement, the company also said its consumer segment was growing steadily with Dream Water inking new agreements with major retailers across North America. It is currently available in over 30,000 stores.
“Although current capital market conditions remain challenging, the company remains focused on delivering on our strategic priorities and building a successful company for the long-term based on solid fundamentals," said Froese.
Cultivation segment
The company said United Greeneries remains on track to secure a capacity target of 20,000 kgs of premium flower in 2020.
There is construction work in progress at both the Mission Road and Lucky Lake facilities. In October 2019, United Greeneries received its cultivation licence for Phase 1 of the new Mission Road facility which, when fully completed, “will triple the production capacity in Duncan and increase operational efficiency,” said the company.
To boost supply, United Greeneries signed a cultivation agreement with Stevens Green that will provide additional supply while maintaining the quality associated with the Royal High brand.
“The first harvest is scheduled for this month which will immediately boost supply for provincial partners,” noted the company.
United Greeneries is one of three licensed producers to complete a pilot program with Shoppers Drug Mart and TruTrace Technologies Inc (CSE:TTT) (OTCMKTS:TTTSF), the medical cannabis verification company.
Contact Uttara Choudhury at uttara@proactiveinvestors.com
Follow her on Twitter: @UttaraProactive
Brief mention: "Blockchain Firm Partners With Cannabis Data App to Create Research Project"
https://cointelegraph.com/news/blockchain-firm-partners-with-cannabis-data-app-to-create-research-project
A blockchain-based data marketplace, Measure Protocol, and a cannabis-oriented survey rewards app, Broccoli, will jointly establish a research community for cannabis users.
According to a Nov. 12 press release, the companies will use the new community to survey consumers, collect data and make reports dedicated to cannabis use and the industry. In doing so, the parties intend to discuss the benefits of cannabis, debunk or prove myths surrounding it, and make the collected information available to the public.
Phillip Olla, co-CEO of Audacia Bioscience, the company that stands behind Broccoli, said that blockchain technology will enable the firms to collect data about cannabis use in a transparent and credible manner, which will help bring cannabis into the mainstream.
Blockchain implementation in the cannabis industry
Other cannabis industry stakeholders have been applying blockchain to different aspects of their business. In late September, decentralized application-focused blockchain Aeternity revealed that it will use blockchain to track the supply chain of Montevideo-based medical and recreational cannabis producer Uruguay Can.
Blockchain tracking startup TruTrace Technologies Inc. partnered with Big Four auditing firm Deloitte to track cannabis using blockchain technology. The system is set to employ the technology to track the plant from seed to sale, in order to guarantee that customers and retailers know the history of the product.
Also, Australian Securities Exchange-listed firm Security Matters filed a patent application in the United States for a blockchain system to securely manage the cannabis supply chain. The proposed system could be applied to mark, track and manage the supply chain for cannabis plants, products and cannabis-derived ingredients.
Nice SOLI email alert showing days trading range!
Came at 6:30 pm.
Revenues as a whole in Q3 2019 increased by 74% or $144,552 in comparison to Q3 2018, primarily because of the increase in sales related to IP license fee income. Services income increased 102%, which included an increase in professional fees.Product revenues increased in Q3 2019 by 50% or $66,070 over Q3 2018 primarily due to the revenue we received from our military sales. IP licensing income from Inventergy in Q3 2019 continued with 5 licensing and settlement agreement executed.
The Company’s goal is to generate recurring subscription revenues from the use of all of our tracking products.
We had a 37% increase in international subscribers and an 11% increase in total subscribers for Q3 2019 compared to Q3 2018.
GTXO fins are out.
Link: https://www.sec.gov/Archives/edgar/data/1375793/000149315219017046/form10-q.htm
tmp118 is correct. GTXO failed to maintain .01.
Hopefully, they'll remedy that!
The OTCQB® Venture Market is for early-stage and developing U.S. and international companies. To be eligible, companies must be current in their reporting and undergo an annual verification and management certification process. Companies must meet $0.01 bid test and may not be in bankruptcy.
Little bit of an "ouch" here:
https://www.proactiveinvestors.com/companies/news/906768/na-proactive-news-snapshot-nemaura-medical-silvercorp-metals-seelos-therapeutics-electrameccanicavehicles--906768.html
Trutrace Technologies Inc (CVE:TTT) has worked out a deal to settle $30,000 in debt owed to a creditor in exchange for the issuance of 250,000 shares at a price of $0.12 per share. Half of the shares issued as part of this debt settlement will be subject to voluntary holding periods. Under this arrangement's terms, 41,666 shares will be released from escrow on November 15 and 41,667 shares on November 22. Lastly, 41,667 shares will be released on November 29. Trutrace’s flagship product is StrainSecure, the first integrated blockchain platform to register and track intellectual property in the cannabis industry. This technology allows cannabis growers and breeders to identify and secure rights to their intellectual property while paring back the costs of quality-control testing for legal cannabis
GTXO Outstanding Shares 66,950,246 11/01/2019
https://www.otcmarkets.com/stock/GTXO/security
Me, too, toytundra.
My favorite Kevin line: "Anyone selling now will get hit (as you know) with short term CG tax instead of long term. "
Referring to the Friends and Family shares.